{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:24:59Z","timestamp":1794468299020,"version":"4.9.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ygyno.2024.11.004","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T12:55:12Z","timestamp":1731416112000},"page":"50-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Adverse events in the placebo arm of SOLO2\/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer"],"prefix":"10.1016","volume":"192","author":[{"given":"Katherine Elizabeth","family":"Francis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Korach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lainez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Chiara","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gropp-Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Khoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.11.004_bb0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2022.04.022","article-title":"Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: a systematic review and meta-analysis","volume":"170","author":"Simon","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2024.11.004_bb0010","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.11.004_bb0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11136-017-1729-8","article-title":"Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer","volume":"27","author":"King","year":"2017","journal-title":"Qual. Life Res."},{"issue":"2","key":"10.1016\/j.ygyno.2024.11.004_bb0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.mayocpiqo.2019.01.002","article-title":"Physician-reported experience and understanding of adverse event attribution in cancer clinical trials","volume":"3","author":"Le-Rademacher","year":"2019","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"issue":"5","key":"10.1016\/j.ygyno.2024.11.004_bb0025","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10637-010-9456-9","article-title":"A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials","volume":"29","author":"Mukherjee","year":"2011","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2024.11.004_bb0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctrv.2019.04.004","article-title":"Improving attribution of adverse events in oncology clinical trials","volume":"76","author":"George","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"12","key":"10.1016\/j.ygyno.2024.11.004_bb0035","doi-asserted-by":"crossref","first-page":"e1050","DOI":"10.1200\/JOP.19.00366","article-title":"Assessing an ASCO decision aid for improving the accuracy and attribution of serious adverse event reporting from investigators to sponsors","volume":"15","author":"Mileham","year":"2019","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.ygyno.2024.11.004_bb0040","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ."},{"issue":"3","key":"10.1016\/j.ygyno.2024.11.004_bb0045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.23.00377","article-title":"Importance of low- and moderate-grade adverse events in patients\u2019 treatment experience and treatment discontinuation: an analysis of the E1912 trial","volume":"42","author":"O\u2019Connell","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.11.004_bb0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.23.01976","article-title":"Patient experience, adverse event reporting, and clinical trial design","volume":"42","author":"Neuman","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2024.11.004_bb0055","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.clinthera.2016.03.011","article-title":"Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in Cancer clinical trials","volume":"38","author":"Basch","year":"2016","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.ygyno.2024.11.004_bb0060","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamaoncol.2019.5566","article-title":"Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials","volume":"6","author":"Atkinson","year":"2020","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.11.004_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.ygyno.2024.11.004_bb0070","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1007\/s00520-016-3297-9","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2024.11.004_bb0075","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S1470-2045(16)00152-2","article-title":"Under-reporting of harm in clinical trials","volume":"17","author":"Seruga","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.11.004_bb0080","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.3332","article-title":"Assessment of adverse events from the patient perspective in a phase 3 metastatic castration-resistant prostate cancer clinical trial","author":"Dueck","year":"2020","journal-title":"JAMA Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T01:17:03Z","timestamp":1738718223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824011971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":16,"alternative-id":["S0090825824011971"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.11.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events in the placebo arm of SOLO2\/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}